 | • レポートコード：C-MOR-100196 • 出版社/出版日：Mordor Intelligence / 2019年9月 • レポート形態：英文、PDF、114ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Multi User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Site License | ￥888,000 (USD6,000) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、救急救命用診断の世界市場について調査・分析し、救急救命用診断の世界市場規模、市場動向、市場環境分析、市場展望、セグメント別分析、地域別分析、関連企業情報など以下の構成でお届け致します。 |
Market Overview
The increasing global prevalence of chronic and lifestyle-related disorders is one of the primary factors which is propelling the critical care diagnostics market. Additionally, rising awareness among people for early diagnosis and treatment, rise in the use of data management and connectivity through interoperability to electronic health record (EHR), and rising adoption of telehealth services and remote communications are the other factors which are propelling the growth of Critical Care Diagnostics Market. However, the high cost of the diagnostic test and lack of skilled professionals in handling the critical care diagnostics are likely to impede the growth of the market.
Scope of the Report
Critical care refers to meeting the needs of the patients who require immediate attention, due to life-threatening health conditions, where the vital organs of the patient’s body are at the risk of failing. The treatment requires advanced therapeutic, monitoring, and diagnostic technology with the objective of stabilizing the functioning of the organs and improving patient conditions.
Key Market Trends
Emergency Rooms are Expected to Lead the Market
The public demand for emergency rooms, where critically ill patients are recommended, is witnessing a steady rise. The survival rate of critically ill patients in the emergency department is directly related to the advancement of early recognition and treatment of diseases. According to the recent article of 2017 published in Science Daily by University of Maryland, the percentage of critical care delivered by the emergency department increased significantly, with nearly half of all the medical care in the United States being delivered by the emergency department. According to the Emergency Medicine Network (EMNet), the United States had an estimated 5,280 emergency departments in 2015, with nearly 151.6 million emergency department visits. A similar pattern of the increasing number of emergency rooms can be observed in the European countries, whereas, the numbers vary considerably in the emerging economies, such as India, China, and Japan.
North America is expected to dominate over the Forecast Period
North America has been witnessing stable growth, but with substantial regional variations. According to a study published in 2015, in American Journal of Respiratory and Critical Care Medicine, the national number of ICU beds increased by around 15%, reaching about 80,000 beds. The growth was highly variable, in line with the population density of each state. The hospitals in the United States have made substantial investments in the physical infrastructure of their operating rooms. More than 60% of the revenue generated from the hospitals in the United States come from the activities in the operating room of an average hospital.
The need for upgrading the technology remains vital for critical care diagnostics and management. This factor is accompanied by the high cost of long hospital stay, which involves an operating room procedure. The hospital costs by themselves are very high. The high healthcare expenditure, better infrastructure, and additional involvement by the government are expected to drive the growth of the market in North America.
Competitive Landscape
The market players are involving with government initiations, through funding and collaboration which can help the Critical Care Diagnostics market to garner significant growth. Top players are also engaged in new product launches, partnerships, collaborations, etc to enhance their market presence. For instance, January 2018 – GE Healthcare entered into the strategic, long-term partnership with Roche to jointly develop digital clinical decision support solutions for cancer and critical care patients. Key players in the market are Abbott, Alere, Inc., Beckman-Coulter, and Roche, among others.
Reasons to Purchase this report:
The market estimate (ME) sheet in Excel format
Report customization as per the client’s requirements
3 months of analyst support
Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in the Prevalence of Chronic Diseases and Lifestyle-related Disorders
4.2.2 Increase in Data Management and Connectivity through Interoperability to Electronic Health Record (EHR)
4.2.3 Rising Demand for Early Diagnosis and Treatment
4.2.4 Rising Adoption of Telehealth Services and Remote Communications
4.3 Market Restraints
4.3.1 High Cost of Molecular Diagnostics Tools
4.3.2 Lack of Skilled Professionals
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Test Type
5.1.1 Flow Cytometry
5.1.2 Hematology Test
5.1.3 Microbiology and Infectious Test
5.1.4 Coagulation Test
5.1.5 Immunoprotein
5.1.6 Routine and Special Chemistry
5.1.7 Others
5.2 By End User
5.2.1 Operating Room
5.2.2 Emergency Room
5.2.3 Intensive Care Unit
5.2.4 Others
5.3 Geography
5.3.1 North America
5.3.1.1 US
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 UK
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott
6.1.2 Bayer AG
6.1.3 Becton, Dickinson & Company
6.1.4 bioMerieux SA
6.1.5 Bio-Rad Laboratories, Inc.
6.1.6 Chembio Diagnostic Systems, Inc.
6.1.7 Danaher Corporation
6.1.8 F. Hoffmann-La Roche
6.1.9 Siemens Healthineers
6.1.10 Sysmex Corporation
7 MARKET OPPORTUNITIES AND FUTURE TRENDS